EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3–TGF-β signaling pathway

Hao Zhang, Tong Xiang, Qiuzhong Pan, Mengjia Song, Lili Huang, Yao-Jun Zhang, Zili Hu, Xinyi Yang, Haoran Zhong, Yingzi Li, Jun Luo, Hao Chen und 3 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Hao Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, STAT3 Transcription Factor, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Science and Technology Projects in Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) remains a major global health burden with limited effective therapeutic strategies. Although chimeric antigen receptor (CAR) T-cell therapy has shown encouraging potential, its efficacy in HCC is profoundly constrained by the immunosuppressive tumor microenvironment.

Methods

In this study, we performed integrative analyses of HCC transcriptomic and clinical samples data to identify Copine-1 (CPNE1) as potential oncogenic drivers involved in tumor progression and immune suppression. Using functional and mechanistic assays in vitro with HCC cell line models and in vivo with mouse models, we examined the role of CPNE1 in regulating tumor proliferation, stemness, and its contribution to resistance against GPC3-targeted CAR-T cell therapy.

Results

We found that CPNE1 is significantly overexpressed in HCC and correlates with poor patient prognosis. Functional assays revealed that CPNE1 enhances tumor proliferation and stemness by activating the STAT3–transforming growth factor beta (TGF-β) signaling pathway. Moreover, CPNE1-induced secretion of TGF-β promotes T-cell exhaustion, which impairs the efficacy of CAR-T cells. Knockdown of CPNE1 restored CAR-T cell function, enhanced T-cell infiltration into tumors, reduced exhaustion, and improved antitumor efficacy without causing systemic toxicity. Clinically, high CPNE1 expression was associated with lower T-cell infiltration and poor outcomes in HCC patients treated with immune checkpoint inhibitors.

Conclusions

These findings identify CPNE1 as a critical regulator of HCC progression and immune suppression, highlighting the CPNE1–STAT3–TGF-β axis as a promising therapeutic target in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsSTAT3 Transcription FactorImmunotherapy, AdoptiveTransforming Growth Factor betaGlypicansHumansAnimalsMiceSignal TransductionNeoplastic Stem CellsReceptors, Chimeric AntigenFemaleCell Line, Tumor

Stichwörter der Autor:innen

Chimeric antigen receptor - CARHepatocellular CarcinomaImmunotherapyStem cell

Substanzen

STAT3 Transcription FactorTransforming Growth Factor betaSTAT3 protein, humanGlypicansGPC3 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China xiajch@mail.sysu.edu.cn yangcp@sysucc.org.cn g…

Förderung

  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Science and Technology Projects in Guangzhou

Zitieren

APA

Zhang, H., Xiang, T., Pan, Q., Song, M., Huang, L., Zhang, Y. J., Hu, Z., Yang, X., Zhong, H., Li, Y., Luo, J., Chen, H., Gao, S., Yang, C., & Xia, J. C. (2026). CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3–TGF-β signaling pathway. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014430

Vancouver

Zhang H, Xiang T, Pan Q, Song M, Huang L, Zhang YJ, et al. CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3–TGF-β signaling pathway. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014430

BibTeX
@article{Zhang2026,
  author = {Zhang, Hao and Xiang, Tong and Pan, Qiuzhong and Song, Mengjia and Huang, Lili and Zhang, Yao-Jun and Hu, Zili and Yang, Xinyi and Zhong, Haoran and Li, Yingzi and Luo, Jun and Chen, Hao and Gao, Song and Yang, Chaopin and Xia, Jian-Chuan},
  title = {CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3–TGF-β signaling pathway},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014430}
}
Kostenlos starten →